Related Experiment Videos
The staging of M+ disease
C Bouffioux1, C Bollack, H Scher
1Department of Urology, CHU Sart Tilman, Liège, Belgium.
Progress in Clinical and Biological Research
|January 1, 1990
Summary
Newly diagnosed prostate cancer patients require thorough staging to detect distant metastases. Investigations include clinical assessment, physical exams, blood tests, and imaging like bone scans and X-rays for effective management.
Area of Science:
- Oncology
- Diagnostic Imaging
- Clinical Pathology
Background:
- Accurate staging of newly diagnosed prostate cancer is crucial for treatment planning.
- Identifying distant metastases impacts patient prognosis and therapeutic strategies.
Framework:
- Utilizes clinical history (weight loss, pain), physical examination (hepatic enlargement, lymph nodes), and performance status.
- Incorporates laboratory tests including hemoglobin, creatinine, prostate-specific antigen (PSA), prostate-acid phosphatase (PAP), alkaline phosphatases, liver function tests, and testosterone levels.
- Recommends imaging modalities such as bone scans with X-rays, chest X-rays, and potentially ultrasound or CT scans for specific indications.
Implementation:
- Follow-up protocols involve regular clinical assessments, physical examinations, performance status evaluation, and laboratory tests every three months.
- Bone scan frequency varies: every six months for clinical trials, annually for good prognosis, and every 3-6 months for poor prognosis.
- Repeat imaging is guided by significant increases (25-50%) in tumor markers (PAP, PSA, alkaline phosphatase) or clinical data, ensuring treatment influence.
Implications:
- Establishes a comprehensive diagnostic and follow-up pathway for prostate cancer staging.
- Optimizes resource utilization by tailoring investigations and follow-up frequency based on prognostic factors and clinical need.
- Aids clinicians in making informed treatment decisions by providing timely and relevant staging information.